| abstract |
Novel antibody-based binders derived from human immunoglobulins and camelid immunoglobulins have been described. These binders recognize and specifically bind to Clostridium difficile toxin A and / or toxin B, and in some cases, exhibit toxin neutralizing activity. These binding agents can be used to treat or prevent primary and recurrent CDI. The said binding agents, camelid V H H peptide monomers, linked V H H peptide monomers group, V H H peptide monomers coupled to the Fc domain of an antibody, and binding to IgG antibodies Modified V H H peptide monomers. [Selection] Figure 8 |